Our finding that the autoimmune syndrome was suppressed by concurrent KD of Hif2a also suggests that the newly developed HIF2α antagonists, currently in clinical trials for the treatment of renal cancer (62), might be assessed in autoimmunity and transplantation. Here, EPAS1 is linked to renal carcinoma.